Efficacy and Safety Profile of Ivosidenib in the Management of Patients with Acute Myeloid Leukemia (AML): An Update on the Emerging Evidence

References

• Döhner H, Estey E, Grimwade D, et al. Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood. 2017;129(4):424–447.
   PubMed Web of Science ®Google Scholar
• DiNardo CD, Jabbour E, Ravandi F, et al. IDH1 and IDH2 mutations in myelodysplastic syndromes and role in disease progression. Leukemia. 2016;30(4):980–984. doi:10.1038/leu.2015.211
   PubMed Web of Science ®Google Scholar
• Rowe JM. Progress and predictions: AML in 2018. Best Pract Res Clin Haematol. 2018;31(4):337–340. doi:10.1016/j.beha.2018.09.002
   Web of Science ®Google Scholar
• Mardis ER, Ding L, Dooling DJ, et al. Recurring mutations found by sequencing an acute myeloid leukemia genome. N Engl J Med. 2009;361(11):1058–1066. doi:10.1056/NEJMoa0903840
   PubMed Web of Science ®Google Scholar
• Donker ML, Ossenkoppele GJ. Evaluating ivosidenib for the treatment of acute myeloid leukemia. Expert Opin Pharmacother. 2020;1–9.
   Web of Science ®Google Scholar
• Warburg O. On the origin of cancer cells. Science. 1956;123(3191):309–314. doi:10.1126/science.123.3191.309
   PubMed Web of Science ®Google Scholar
• Vander Heiden MG, Cantley LC, Thompson CB. Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science. 2009;324(5930):1029–1033. doi:10.1126/science.1160809
   PubMed Web of Science ®Google Scholar
• Molenaar RJ, Maciejewski JP, Wilmink JW, van Noorden CJF. Wild-type and mutated IDH1/2 enzymes and therapy responses. Oncogene. 2018;37(15):1949–1960. doi:10.1038/s41388-017-0077-z
   PubMed Web of Science ®Google Scholar
• Avellaneda Matteo D, Grunseth AJ, Gonzalez ER, et al. Molecular mechanisms of isocitrate dehydrogenase 1 (IDH1) mutations identified in tumors: the role of size and hydrophobicity at residue 132 on catalytic efficiency. J Biol Chem. 2017;292(19):7971–7983. doi:10.1074/jbc.M117.776179
   Web of Science ®Google Scholar
• Losman J-A, Looper RE, Koivunen P, et al. (R)-2-hydroxyglutarate is sufficient to promote leukemogenesis and its effects are reversible. Science. 2013;339(6127):1621–1625. doi:10.1126/science.1231677
   PubMed Web of Science ®Google Scholar
• McCarthy N. Leukaemia: knowing left from right. Nat Rev Cancer. 2013;13(4):220–221. doi:10.1038/nrc3487
   Web of Science ®Google Scholar
• Popovici-Muller J, Lemieux RM, Artin E, et al. Discovery of AG-120 (Ivosidenib): a first-in-class mutant IDH1 inhibitor for the treatment of IDH1 mutant cancers. ACS Med Chem Lett. 2018;9(4):300–305. doi:10.1021/acsmedchemlett.7b00421
   PubMed Web of Science ®Google Scholar
• Parsons DW, Jones S, Zhang X, et al. An integrated genomic analysis of human glioblastoma multiforme. Science. 2008;321(5897):1807–1812. doi:10.1126/science.1164382
   PubMed Web of Science ®Google Scholar
• Losman J-A, Kaelin WG. What a difference a hydroxyl makes: mutant IDH, (R)-2-hydroxyglutarate, and cancer. Genes Dev. 2013;27(8):836–852. doi:10.1101/gad.217406.113
   PubMed Web of Science ®Google Scholar
• Yan H, Parsons DW, Jin G, et al. IDH1 and IDH2 mutations in gliomas. N Engl J Med. 2009;360(8):765–773. doi:10.1056/NEJMoa0808710
   PubMed Web of Science ®Google Scholar
• Boscoe AN, Rolland C, Kelley RK. Frequency and prognostic significance of isocitrate dehydrogenase 1 mutations in cholangiocarcinoma: a systematic literature review. J Gastrointest Oncol. 2019;10(4):751–765. doi:10.21037/jgo.2019.03.10
   PubMed Web of Science ®Google Scholar
• Green A, Beer P. Somatic mutations of IDH1 and IDH2 in the leukemic transformation of myeloproliferative neoplasms. N Engl J Med. 2010;362(4):369–370. doi:10.1056/NEJMc0910063
   PubMed Web of Science ®Google Scholar
• Schnittger S, Haferlach C, Ulke M, Alpermann T, Kern W, Haferlach T. IDH1 mutations are detected in 6.6% of 1414 AML patients and are associated with intermediate risk karyotype and unfavorable prognosis in adults younger than 60 years and unmutated NPM1 status. Blood. 2010;116(25):5486–5496. doi:10.1182/blood-2010-02-267955
   PubMed Web of Science ®Google Scholar
• Papaemmanuil E, Gerstung M, Bullinger L, et al. Genomic classification and prognosis in acute myeloid leukemia. N Engl J Med. 2016;374(23):2209–2221. doi:10.1056/NEJMoa1516192
   PubMed Web of Science ®Google Scholar
• Kao H-W, Liang DC, Kuo M-C, et al. High frequency of additional gene mutations in acute myeloid leukemia with MLL partial tandem duplication: DNMT3A mutation is associated with poor prognosis. Oncotarget. 2015;6(32):33217–33225. doi:10.18632/oncotarget.5202
   Google Scholar
• Nassereddine S, Lap CJ, Tabbara IA. Evaluating ivosidenib for the treatment of relapsed/refractory AML: design, development, and place in therapy. Onco Targets Ther. 2019;12:303–308. doi:10.2147/OTT.S182443
   PubMed Web of Science ®Google Scholar
• Kosmider O, Gelsi-Boyer V, Slama L, et al. Mutations of IDH1 and IDH2 genes in early and accelerated phases of myelodysplastic syndromes and MDS/myeloproliferative neoplasms. Leukemia. 2010;24(5):1094–1096. doi:10.1038/leu.2010.52
   PubMed Web of Science ®Google Scholar
• Desai P, Mencia-Trinchant N, Savenkov O, et al. Somatic mutations precede acute myeloid leukemia years before diagnosis. Nat Med. 2018;24(7):1015–1023. doi:10.1038/s41591-018-0081-z
   PubMed Web of Science ®Google Scholar
• Luque Paz D, Jouanneau-Courville R, Riou J, et al. Leukemic evolution of polycythemia vera and essential thrombocythemia: genomic profiles predict time to transformation. Blood Adv. 2020;4(19):4887–4897. doi:10.1182/bloodadvances.2020002271
   PubMed Web of Science ®Google Scholar
• Haferlach T, Nagata Y, Grossmann V, et al. Landscape of genetic lesions in 944 patients with myelodysplastic syndromes. Leukemia. 2014;28(2):241–247. doi:10.1038/leu.2013.336
   PubMed Web of Science ®Google Scholar
• Molenaar RJ, Thota S, Nagata Y, et al. Clinical and biological implications of ancestral and non-ancestral IDH1 and IDH2 mutations in myeloid neoplasms. Leukemia. 2015;29(11):2134–2142. doi:10.1038/leu.2015.91
   PubMed Web of Science ®Google Scholar
• Testa U, Castelli G, Pelosi E. Isocitrate dehydrogenase mutations in myelodysplastic syndromes and in acute myeloid leukemias. Cancers (Basel). 2020;12(9). doi:10.3390/cancers12092427
   Web of Science ®Google Scholar
• Makishima H, Yoshizato T, Yoshida K, et al. Dynamics of clonal evolution in myelodysplastic syndromes. Nat Genet. 2017;49(2):204–212. doi:10.1038/ng.3742
   PubMed Web of Science ®Google Scholar
• Patnaik MM, Hanson CA, Hodnefield JM, et al. Differential prognostic effect of IDH1 versus IDH2 mutations in myelodysplastic syndromes: a Mayo Clinic Study of 277 patients. Leukemia. 2012;26(1):101–105. doi:10.1038/leu.2011.298
   PubMed Web of Science ®Google Scholar
• Wang N, Wang F, Shan N, Sui X, Xu H. IDH1 mutation is an independent inferior prognostic indicator for patients with myelodysplastic syndromes. Acta Haematol. 2017;138(3):143–151. doi:10.1159/000479546
   Web of Science ®Google Scholar
• Bruneau J, Molina TJ. WHO classification of tumors of hematopoietic and lymphoid tissues. In: van Krieken JHJM, editor. Encyclopedia of Pathology. Cham: Springer International Publishing; 2019:1–5.
   Google Scholar
• Tefferi A, Lasho TL, Finke CM, et al. Targeted deep sequencing in primary myelofibrosis. Blood Adv. 2016;1(2):105–111. doi:10.1182/bloodadvances.2016000208
   PubMed Web of Science ®Google Scholar
• Pardanani A, Lasho TL, Finke CM, Mai M, McClure RF, Tefferi A. IDH1 and IDH2 mutation analysis in chronic- and blast-phase myeloproliferative neoplasms. Leukemia. 2010;24(6):1146–1151. doi:10.1038/leu.2010.77
   PubMed Web of Science ®Google Scholar
• Bartels S, Faisal M, Büsche G, et al. Mutations associated with age-related clonal hematopoiesis in PMF patients with rapid progression to myelofibrosis. Leukemia. 2020;34(5):1364–1372. doi:10.1038/s41375-019-0668-5
   Web of Science ®Google Scholar
• Lasho TL, Jimma T, Finke CM, et al. SRSF2 mutations in primary myelofibrosis: significant clustering with IDH mutations and independent association with inferior overall and leukemia-free survival. Blood. 2012;120(20):4168–4171. doi:10.1182/blood-2012-05-429696
   PubMed Web of Science ®Google Scholar
• Tefferi A, Jimma T, Sulai NH, et al. IDH mutations in primary myelofibrosis predict leukemic transformation and shortened survival: clinical evidence for leukemogenic collaboration with JAK2V617F. Leukemia. 2012;26(3):475–480. doi:10.1038/leu.2011.253
   PubMed Web of Science ®Google Scholar
• Chifotides HT, Masarova L, Alfayez M, et al. Outcome of patients with IDH1/2-mutated post-myeloproliferative neoplasm AML in the era of IDH inhibitors. Blood Adv. 2020;4(21):5336–5342. doi:10.1182/bloodadvances.2020001528
   Web of Science ®Google Scholar
• Paschka P, Schlenk RF, Gaidzik VI, et al. IDH1 and IDH2 mutations are frequent genetic alterations in acute myeloid leukemia and confer adverse prognosis in cytogenetically normal acute myeloid leukemia with NPM1 mutation without FLT3 internal tandem duplication. J Clin Oncol. 2010;28(22):3636–3643. doi:10.1200/JCO.2010.28.3762
   PubMed Web of Science ®Google Scholar
• Patel JP, Gönen M, Figueroa ME, et al. Prognostic relevance of integrated genetic profiling in acute myeloid leukemia. N Engl J Med. 2012;366(12):1079–1089. doi:10.1056/NEJMoa1112304
   PubMed Web of Science ®Google Scholar
• Falini B, Spinelli O, Meggendorfer M, et al. IDH1-R132 changes vary according to NPM1 and other mutations status in AML. Leukemia. 2019;33(4):1043–1047. doi:10.1038/s41375-018-0299-2
   Web of Science ®Google Scholar
• Figueroa ME, Abdel-Wahab O, Lu C, et al. Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation. Cancer Cell. 2010;18(6):553–567. doi:10.1016/j.ccr.2010.11.015
   PubMed Web of Science ®Google Scholar
• Green CL, Evans CM, Hills RK, Burnett AK, Linch DC, Gale RE. The prognostic significance of IDH1 mutations in younger adult patients with acute myeloid leukemia is dependent on FLT3/ITD status. Blood. 2010;116(15):2779–2782. doi:10.1182/blood-2010-02-270926
   PubMed Web of Science ®Google Scholar
• DiNardo CD, Ravandi F, Agresta S, et al. Characteristics, clinical outcome, and prognostic significance of IDH mutations in AML. Am J Hematol. 2015;90(8):732–736. doi:10.1002/ajh.24072
   PubMed Web of Science ®Google Scholar
• Xu Q, Li Y, Lv N, et al. Correlation between isocitrate dehydrogenase gene aberrations and prognosis of patients with acute myeloid leukemia: a systematic review and meta-analysis. Clin Cancer Res. 2017;23(15):4511–4522. doi:10.1158/1078-0432.CCR-16-2628
   PubMed Web of Science ®Google Scholar
• Dunlap JB, Leonard J, Rosenberg M, et al. The combination of NPM1, DNMT3A, and IDH1/2 mutations leads to inferior overall survival in AML. Am J Hematol. 2019;94(8):913–920. doi:10.1002/ajh.25517
   PubMed Web of Science ®Google Scholar
• Suijker J, Oosting J, Koornneef A, et al. Inhibition of mutant IDH1 decreases D-2-HG levels without affecting tumorigenic properties of chondrosarcoma cell lines. Oncotarget. 2015;6(14):12505–12519. doi:10.18632/oncotarget.3723
   PubMedGoogle Scholar
• Fan B, Mellinghoff IK, Wen PY, et al. Clinical pharmacokinetics and pharmacodynamics of ivosidenib, an oral, targeted inhibitor of mutant IDH1, in patients with advanced solid tumors. Invest New Drugs. 2020;38(2):433–444. doi:10.1007/s10637-019-00771-x
   PubMed Web of Science ®Google Scholar
• Dai D, Yang H, Nabhan S, et al. Effect of itraconazole, food, and ethnic origin on the pharmacokinetics of ivosidenib in healthy subjects. Eur J Clin Pharmacol. 2019;75(8):1099–1108. doi:10.1007/s00228-019-02673-6
   PubMed Web of Science ®Google Scholar
• Megías-Vericat JE, Solana-Altabella A, Ballesta-López O, Martínez-Cuadrón D, Montesinos P. Drug-drug interactions of newly approved small molecule inhibitors for acute myeloid leukemia. Ann Hematol. 2020;99(9):1989–2007. doi:10.1007/s00277-020-04186-0
   PubMed Web of Science ®Google Scholar
• DiNardo CD, Stein EM, de Botton S, et al. Durable remissions with ivosidenib in IDH1-mutated relapsed or refractory AML. N Engl J Med. 2018;378(25):2386–2398. doi:10.1056/NEJMoa1716984
   PubMed Web of Science ®Google Scholar
• Norsworthy KJ, Luo L, Hsu V, et al. FDA approval summary: ivosidenib for relapsed or refractory acute myeloid leukemia with an isocitrate dehydrogenase-1 mutation. Clin Cancer Res. 2019;25(11):3205–3209. doi:10.1158/1078-0432.CCR-18-3749
   PubMed Web of Science ®Google Scholar
• DiNardo CD, Stein EM. SOHO state of the art update and next questions: IDH therapeutic targeting in AML. Clin Lymphoma Myeloma Leuk. 2018;18(12):769–772. doi:10.1016/j.clml.2018.10.007
   Web of Science ®Google Scholar
• Maertens JA, Girmenia C, Brüggemann RJ, et al. European guidelines for primary antifungal prophylaxis in adult haematology patients: summary of the updated recommendations from the European Conference on Infections in Leukaemia. J Antimicrob Chemother. 2018;73(12):3221–3230. doi:10.1093/jac/dky286
   PubMed Web of Science ®Google Scholar
• Safdar A, Rodriguez GH. Aerosolized amphotericin B lipid complex as adjunctive treatment for fungal lung infection in patients with cancer-related immunosuppression and recipients of hematopoietic stem cell transplantation. Pharmacotherapy. 2013;33(10):1035–1043. doi:10.1002/phar.1309
   Web of Science ®Google Scholar
• Boutzen H, Saland E, Larrue C, et al. Isocitrate dehydrogenase 1 mutations prime the all-trans retinoic acid myeloid differentiation pathway in acute myeloid leukemia. J Exp Med. 2016;213(4):483–497. doi:10.1084/jem.20150736
   PubMed Web of Science ®Google Scholar
• Birendra KC, DiNardo CD. Evidence for clinical differentiation and differentiation syndrome in patients with acute myeloid leukemia and IDH1 mutations treated with the targeted mutant IDH1 inhibitor, AG-120. Clin Lymphoma Myeloma Leuk. 2016;16(8):460–465. doi:10.1016/j.clml.2016.04.006
   PubMed Web of Science ®Google Scholar
• Hernandez Burgos P, Patel J, Chen A. Ivosidenib induction therapy complicated by myopericarditis and cardiogenic shock: a case report and literature review. J Oncol Pharm Pract. 2020;26(3):754–757. doi:10.1177/1078155219865934
   Web of Science ®Google Scholar
• Norsworthy KJ, Mulkey F, Scott EC, et al. Differentiation syndrome with ivosidenib and enasidenib treatment in patients with relapsed or refractory IDH-mutated AML: a U.S. food and drug administration systematic analysis. Clin Cancer Res. 2020;26(16):4280–4288. doi:10.1158/1078-0432.CCR-20-0834
   PubMed Web of Science ®Google Scholar
• Martelli MP, Martino G, Cardinali V, Falini B, Martinelli G, Cerchione C. Enasidenib and ivosidenib in AML. Minerva Med. 2020;111(5). doi:10.23736/S0026-4806.20.07024-X
   Web of Science ®Google Scholar
• Roboz GJ, DiNardo CD, Stein EM, et al. Ivosidenib induces deep durable remissions in patients with newly diagnosed IDH1-mutant acute myeloid leukemia. Blood. 2020;135(7):463–471. doi:10.1182/blood.2019002140
   PubMed Web of Science ®Google Scholar
• Stein EM, DiNardo CD, Fathi AT, et al. Ivosidenib or enasidenib combined with intensive chemotherapy in patients with newly diagnosed AML: a phase 1 study. Blood. 2020;135(7):463–471.
   Google Scholar
• FDA approves ivosidenib as first-line treatment for AML with IDH1 mutation. FDA [Internet]. [ cited August 31, 2020]. Available from: https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-ivosidenib-first-line-treatment-aml-idh1-mutation. Accessed May 25, 2021.
   Google Scholar
• Choe S, Wang H, DiNardo CD, et al. Molecular mechanisms mediating relapse following ivosidenib monotherapy in IDH1-mutant relapsed or refractory AML. Blood Adv. 2020;4(9):1894–1905. doi:10.1182/bloodadvances.2020001503
   PubMed Web of Science ®Google Scholar
• Harding JJ, Lowery MA, Shih AH, et al. Isoform switching as a mechanism of acquired resistance to mutant isocitrate dehydrogenase inhibition. Cancer Discov. 2018;8(12):1540–1547. doi:10.1158/2159-8290.CD-18-0877
   PubMed Web of Science ®Google Scholar
• DiNardo CD, Jonas BA, Pullarkat V, et al. Azacitidine and venetoclax in previously untreated acute myeloid leukemia. N Engl J Med. 2020;383(7):617–629. doi:10.1056/NEJMoa2012971
   PubMed Web of Science ®Google Scholar
• Tiong IS, Dillon R, Ivey A, et al. Venetoclax induces rapid elimination of NPM1 mutant measurable residual disease in combination with low-intensity chemotherapy in acute myeloid leukaemia. Br J Haematol. 2020;192(6):1026–1030. doi:10.1111/bjh.16722
   Web of Science ®Google Scholar
• Wei AH, Montesinos P, Ivanov V, et al. Venetoclax plus LDAC for newly diagnosed AML ineligible for intensive chemotherapy: a Phase 3 randomized placebo-controlled trial. Blood. 2020;135(24):2137–2145. doi:10.1182/blood.2020004856
   PubMed Web of Science ®Google Scholar
• Dinardo C, Takahashi K, Kadia T, et al. Pf291 a phase 1b/2 clinical study of targeted idh1 inhibition with ivosidenib, in combination with the bcl-2 inhibitor venetoclax, for patients with idh1-mutated (midh1) myeloid malignancies. HemaSphere. 2019;3(S1):97. doi:10.1097/01.HS9.0000559376.17429.23
   Google Scholar
• Chan SM, Thomas D, Corces-Zimmerman MR, et al. Isocitrate dehydrogenase 1 and 2 mutations induce BCL-2 dependence in acute myeloid leukemia. Nat Med. 2015;21(2):178–184. doi:10.1038/nm.3788
   PubMed Web of Science ®Google Scholar
• Ma R, Yun C-H. Crystal structures of pan-IDH inhibitor AG-881 in complex with mutant human IDH1 and IDH2. Biochem Biophys Res Commun. 2018;503(4):2912–2917. doi:10.1016/j.bbrc.2018.08.068
   PubMed Web of Science ®Google Scholar
• Goldenson BH, Goodman AM, Ball ED, Goldenson BH, Goodman AM, Ball ED. Gemtuzumab ozogamicin for the treatment of acute myeloid leukemia in adults. Expert Opin Biol Ther. 2020;1–14. doi:10.1080/14712598.2021.1825678
   Web of Science ®Google Scholar
• Lambert J, Pautas C, Terré C, et al. Gemtuzumab ozogamicin for de novo acute myeloid leukemia: final efficacy and safety updates from the open-label, Phase III ALFA-0701 trial. Haematologica. 2019;104(1):113–119. doi:10.3324/haematol.2018.188888
   PubMed Web of Science ®Google Scholar
• Stone RM, Mandrekar SJ, Sanford BL, et al. Midostaurin plus chemotherapy for acute myeloid leukemia with a FLT3 mutation. N Engl J Med. 2017;377(5):454–464. doi:10.1056/NEJMoa1614359
   PubMed Web of Science ®Google Scholar
• DiNardo CD, Tiong IS, Quaglieri A, et al. Molecular patterns of response and treatment failure after frontline venetoclax combinations in older patients with AML. Blood. 2020;135(11):791–803. doi:10.1182/blood.2019003988
   PubMed Web of Science ®Google Scholar
• Lachowiez CA, Borthakur G, Loghavi S, et al. Phase Ib/II study of the IDH1-mutant inhibitor ivosidenib with the BCL2 inhibitor venetoclax ± azacitidine in IDH1-mutated hematologic malignancies. JCO. 2020;38(15_suppl):7500. doi:10.1200/JCO.2020.38.15_suppl.7500
   Web of Science ®Google Scholar